{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:49:02Z","timestamp":1790336942956,"version":"4.1.0"},"reference-count":45,"publisher":"European Respiratory Society (ERS)","issue":"130","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2013,10,9]]},"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:p>The past two decades have seen significant improvements in the management of patients with pulmonary arterial hypertension (PAH). Although outcome has improved, long-term prognosis remains unsatisfactory. The development of new treatment options is clearly important. Equally important is testing new agents in trials designed to provide robust evidence for sustained clinical benefits enabling clinicians to determine the optimal treatment strategy for individual patients. End-points such as the change in 6-min walk distance (6MWD) have been pivotal in the registration trials of currently available PAH-specific therapies. However, as current clinical trials enrol patients with milder disease, many already on background therapy, there is growing evidence that change from baseline in 6MWD is a weak surrogate of outcome in PAH. In addition, while short-term trials allowed for the rapid approval of PAH therapies in the past, there is increasing recognition that clinical trials for new agents must provide evidence of long-term benefits. Clinical trials need to evolve to provide the long-term, clinically relevant data required to appropriately assess new therapies. Event-driven long-term morbidity and mortality trials are currently underway, and will provide robust data on the frequency and timing of events, and are likely to reflect the future of clinical trial design in PAH.<\/jats:p>","DOI":"10.1183\/09059180.00006413","type":"journal-article","created":{"date-parts":[[2013,11,30]],"date-time":"2013-11-30T01:42:15Z","timestamp":1385775735000},"page":"495-502","source":"Crossref","is-referenced-by-count":13,"title":["New perspectives in long-term outcomes in clinical trials of pulmonary arterial hypertension"],"prefix":"10.1183","volume":"22","author":[{"given":"Ioana R.","family":"Preston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Suissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2013,11,29]]},"reference":[{"key":"2025042406001836000_22.130.495.1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00057010"},{"key":"2025042406001836000_22.130.495.2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00196611"},{"key":"2025042406001836000_22.130.495.3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.898122"},{"key":"2025042406001836000_22.130.495.4","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00094112"},{"key":"2025042406001836000_22.130.495.5","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00008211"},{"key":"2025042406001836000_22.130.495.6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.963983"},{"key":"2025042406001836000_22.130.495.7","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-112-7-485"},{"key":"2025042406001836000_22.130.495.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602013340504"},{"key":"2025042406001836000_22.130.495.9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"key":"2025042406001836000_22.130.495.10","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.165.6.2106079"},{"key":"2025042406001836000_22.130.495.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2009.09.005"},{"key":"2025042406001836000_22.130.495.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)01786-2"},{"key":"2025042406001836000_22.130.495.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(03)00463-7"},{"key":"2025042406001836000_22.130.495.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020204"},{"key":"2025042406001836000_22.130.495.15","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200603-358OC"},{"key":"2025042406001836000_22.130.495.16","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1183\/09031936.06.00057906","article-title":"Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension","volume":"4","author":"Hoeper","year":"2006","journal-title":"Eur Respir J"},{"key":"2025042406001836000_22.130.495.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06250-X"},{"key":"2025042406001836000_22.130.495.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012212"},{"key":"2025042406001836000_22.130.495.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60919-8"},{"key":"2025042406001836000_22.130.495.20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.630715"},{"key":"2025042406001836000_22.130.495.21","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.04.00028404"},{"key":"2025042406001836000_22.130.495.22","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200410-1411OC"},{"key":"2025042406001836000_22.130.495.23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.742510"},{"key":"2025042406001836000_22.130.495.24","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200307-957OC"},{"key":"2025042406001836000_22.130.495.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.01.057"},{"key":"2025042406001836000_22.130.495.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2011.10.002"},{"key":"2025042406001836000_22.130.495.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2003.10.056"},{"key":"2025042406001836000_22.130.495.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050010"},{"key":"2025042406001836000_22.130.495.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2005.09.006"},{"key":"2025042406001836000_22.130.495.30","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-8-200810210-00004"},{"key":"2025042406001836000_22.130.495.31","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.839274"},{"key":"2025042406001836000_22.130.495.32","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201101-0093OC"},{"key":"2025042406001836000_22.130.495.33","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.1067\/mhj.2002.121806","article-title":"Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension","volume":"43","author":"Langleben","year":"2002","journal-title":"Am Heart J"},{"key":"2025042406001836000_22.130.495.34","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201001-0123OC"},{"key":"2025042406001836000_22.130.495.35","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.000765"},{"key":"2025042406001836000_22.130.495.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.04.007"},{"key":"2025042406001836000_22.130.495.37","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5403"},{"key":"2025042406001836000_22.130.495.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.01.083"},{"key":"2025042406001836000_22.130.495.39","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.105890"},{"key":"2025042406001836000_22.130.495.40","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200803-029SK"},{"key":"2025042406001836000_22.130.495.41","unstructured":"Fleming TR Harrington DP . Counting Processes and Survival Analysis. Wiley Series in Probability and Statistics. New York, Wiley, 1991."},{"key":"2025042406001836000_22.130.495.42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213917"},{"key":"2025042406001836000_22.130.495.43","unstructured":"A multicenter, double-blind, placebo-controlled phase 3 study to demonstrate the efficacy and safety of ACT-293987 in patients with pulmonary arterial hypertension. NCT01106014 . http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01106014 Date last accessed: June 19, 2013. Date last updated: September 3, 2013."},{"key":"2025042406001836000_22.130.495.44","unstructured":"Effects of the combination of bosentan and sildenafil versus sildenafil monotherapy on pulmonary arterial hypertension (PAH) (Compass 2). NCT00303459 . http:\/\/clinicaltrials.gov\/show\/nct00303459 Date last accessed: June 19, 2013. Date last updated: August 30, 2013."},{"key":"2025042406001836000_22.130.495.45","unstructured":"A randomised, multicenter study of first-line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH). NCT01178073 . http:\/\/clinicaltrials.gov\/show\/NCT01178073 Date last accessed: June 19, 2013. Date last updated: June 6, 2013."}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/09059180.00006413","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T13:00:50Z","timestamp":1745499650000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/09059180.00006413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,29]]},"references-count":45,"journal-issue":{"issue":"130","published-online":{"date-parts":[[2013,11,29]]},"published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.1183\/09059180.00006413"],"URL":"https:\/\/doi.org\/10.1183\/09059180.00006413","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,29]]}}}